MedTrace Logo

A Safety and Efficacy of DRM02 in Subjects With Atopic Dermatitis

NCT01993420 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2021-07-20

No results posted yet for this study

Summary

The purpose of this study is to determine whether DRM02 is safe and effective in the treatment of atopic dermatitis when applied twice daily for 6 weeks.

Conditions

Interventions

DRUG

DRM02

OTHER

Vehicle

Sponsors & Collaborators

  • Dermira, Inc.

    lead INDUSTRY

Principal Investigators

  • Beth Zib · Dermira, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-10-31
Primary Completion
2014-02-28
Completion
2014-03-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01993420 on ClinicalTrials.gov